Related Experiment Video
Updated: Jun 16, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
The pre-diabetic epidemiological study in Depok, West Java
Em Yunir1, Sarwono Waspadji, Ekowati Rahajeng
1Department of Internal Medicine, University of Indonesia, Jakarta Pusat, Republic of Indonesia. dr_yunir@yahoo.com
Objective:
To recognize the prevalence of impaired fasting glucose level (IFG) and impaired glucose tolerance (IGT) in general population of Depok Area, West Java.
Methods:
the study was conducted in a population with age > or = 25 years, in Depok Area, West Java, which was selected by using two stage random sampling. Data were collected by using the Step Wise Approach of WHO. Subjects without previous diabetes history were categorized as diabetes if their fasting blood glucose level > or = 126 mg/dL, and or the 2-hour-after 75 gram glucose load > or = 200 mg/dL. While pre-diabetes was defined as IFG when the fasting blood glucose > or = 100 mg/dL to < 126 mg/dL or IGT when the 2-hour-after 75 gram glucose load level > or = 200 mg/dL (ADA 2003).
Results:
of 1200 participants, there were 975 participants who fulfilled the invitation and there were 969 eligible participants to be evaluated. Among the participants aged > or = 25 years, there were 40 (4.13%) subjects with isolated IFG and 234 (24.25%) subjects with isolated IGT, 55 subjects (5.68%) with mixed IFG/IGT.
Conclusion:
the prevalence of isolated impaired fasting blood glucose in population with age > or = 25 years is 4.13%; while the prevalence of isolated impaired glucose tolerance is 24.25%. Mixed IFG/IGT is 5.68%. The total prevalence of pre-diabetic patients is 33.96%.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes II: Pathophysiology
Type II Diabetes I: Introduction
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type I Diabetes II: Pathophysiology
Type I Diabetes III: Clinical Manifestations